Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-09-27
2005-09-27
Raymond, Richard L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S365000, C514S369000, C514S372000, C514S396000, C514S398000, C514S427000, C548S193000, C548S203000, C548S205000, C548S214000, C548S235000, C548S240000, C548S300100, C548S400000, C548S577000, C549S029000, C549S062000, C549S065000, C549S263000, C549S295000, C549S323000
Reexamination Certificate
active
06949536
ABSTRACT:
This invention provides a compound of the formula:or its pharmaceutically acceptable salt thereof, wherein A is partially unsaturated or unsaturated five membered heterocyclic, or partially unsaturated or unsaturated five membered carbocyclic, wherein the 4-(sulfonyl)phenyl and the 4-substituted phenyl in the formula (I) are attached to ring atoms of Ring A, which are adjacent to each other; R1is optionally substituted aryl or heteroaryl, with the proviso that when A is pyrazole, R1is heteroaryl; R2is C1-4alkyl; halo-substituted C1-4alkyl, C1-4alkylamino, C1-4dialkylamino or amino; R3, R4and R5are independently hydrogen, halo, C1-4alkyl, halo-substituted C1-4alkyl or the like; or two of R3, R4and R5are taken together with atoms to which they are attached and form a 4-7 membered ring. R6and R7are independently hydrogen, halo, C1-4alkyl, halo-substituted C1-4alkyl, C1-4alkoxy, C1-4alkylthio, C1-4alkylamino or N,N-di C1-4alkylamino; and m and n are independently 1, 2, 3 or 4.This invention also provides a pharmaceutical composition useful for the treatment of a medical condition in which prostaglandins are implicated as pathogens.
REFERENCES:
patent: 3839325 (1974-10-01), Hoffstadt
patent: 3896145 (1975-07-01), Berger et al.
patent: 4071466 (1978-01-01), Schroeder et al.
patent: 4259504 (1981-03-01), Lang, Jr. et al.
patent: 4329463 (1982-05-01), Lang, Jr. et al.
patent: 5134142 (1992-07-01), Mataso et al.
patent: 5466823 (1995-11-01), Talley et al.
patent: 5474995 (1995-12-01), Ducharme et al.
patent: 5504215 (1996-04-01), Talley et al.
patent: 5508426 (1996-04-01), Talley et al.
patent: 5516907 (1996-05-01), Talley et al.
patent: 5521207 (1996-05-01), Graneto
patent: 5550142 (1996-08-01), Ducharme et al.
patent: 5585504 (1996-12-01), Desmond et al.
patent: 5668161 (1997-09-01), Talley et al.
patent: 5710140 (1998-01-01), Ducharme et al.
patent: 5756350 (1998-05-01), Lee et al.
patent: 5756529 (1998-05-01), Isakson et al.
patent: 5756530 (1998-05-01), Lee et al.
patent: 5760068 (1998-06-01), Talley et al.
patent: 5792778 (1998-08-01), DeLaszio et al.
patent: 5840746 (1998-11-01), Ducharme et al.
patent: 5866596 (1999-02-01), Sartori et al.
patent: 5869516 (1999-02-01), Arlt et al.
patent: 5892053 (1999-04-01), Zhi et al.
patent: 5994381 (1999-11-01), Haruta et al.
patent: 6294558 (2001-09-01), Ando et al.
patent: 6608095 (2003-08-01), Ando et al.
patent: 6727238 (2004-04-01), Ando et al.
patent: 0418845 (1990-09-01), None
patent: 0554829 (1993-08-01), None
patent: 743304 (1996-11-01), None
patent: 2752576 (1998-02-01), None
patent: 1377247 (1974-12-01), None
patent: WO9500501 (1995-01-01), None
patent: WO9515315 (1995-06-01), None
patent: WO9515316 (1995-06-01), None
patent: WO9515317 (1995-06-01), None
patent: WO9515318 (1995-06-01), None
patent: 9603387 (1996-02-01), None
patent: WO9603387 (1996-02-01), None
patent: WO9603392 (1996-02-01), None
patent: 9603392 (1996-02-01), None
patent: WO9619469 (1996-06-01), None
patent: WO9636617 (1996-11-01), None
patent: WO9711701 (1997-04-01), None
patent: WO9711704 (1997-04-01), None
patent: WO9713755 (1997-04-01), None
patent: WO9727181 (1997-07-01), None
patent: WO9816227 (1998-04-01), None
patent: WO9822442 (1998-05-01), None
patent: WO9843648 (1998-10-01), None
patent: WO9850075 (1998-11-01), None
Chemical Abstract DN 59:35876, also cited as Tischesche et al, Tetrahedron 19,621-34(1963).
Chemical Abstract DN 126:59948, also cited as EP 743304, dated Nov. 1996).
Chemical Abstract DN 37:3564, also cited as Gazzetta Italis, 72, 97-9(1942).
Chemical Abstract DN 95:17984, also cited as Lombardino et al, J. Medicinal Chem. 24/7,830-4(1981).
Chemical Abstract DN 73:106778, also cited as Flores et al, J. Pharmacology and Experimental Therapeutics, 174/3,463-72(1970).
Prasit, et al., “Selective Cyclooxygenase-2-Inhibitors”Ann. Reports Med. Chem. 32, pp. 211-220 (1997).
Cecil Textbook of Medicine, 19thEdition, vol.2, p. 2075 (1996).
Callaghan, et al., “Synthesis of 1H-4, 1,2-benzothiadiazines from substituted N-acetyl-N-aryl-N'thioraoylhydrazines”,J. Chem. Soc.. Perkin Trans. 1(14), pp. 1386-1390 (1975).
Bulletin De La Société Chimique De France, Société Francaise De Chimie, Paris, Fr. Pp. 490-494 (1960).
PubMed Abstr. 12195419, Galli G. et al' G. Ital Nefrol 19/2, 199-203 (2002).
PubMed Abstr. 12110513, Hocherl et al; Am. J. Physiol. Renal Physiol., 283/2, F294-301 (2002).
PubMed Abstr. 12086293, Konstam et al; Cleve Clin J Med., 69/1, 147-52 (2002).
PubMed Abstr. 12075734, Davies et al; Ann Oncol, 13/5, 669-78 (2002).
PubMed Abstr. 12055598, Sigthorsson et al; Gastroeneterology, 122/7, 1913-23 (2002).
PubMed Abstr. 12032335, Rocca et al; Proc Natl Acad Sci USA, 99/11, 7634-9 (2002).
Chemical Abstract DN 128:257325, also cited as FR 2752576, dated Feb. 1998.
Chemical Abstract DN 125:33647, also cited as WO 9603387, dated Feb. 1996.
Chemical Abstract DN 125:33628, also cited as WO 9603392, dated Feb. 1996.
Ando Kazuo
Kato Tomoki
Kawai Akiyoshi
Nonomura Tomomi
Hosley Mary J.
Munchhof Martha G.
Patel Sudhaker B.
Pfizer Inc.
Raymond Richard L.
LandOfFree
Sulfonylbenzene compounds as anti-inflammatory/analgesic agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Sulfonylbenzene compounds as anti-inflammatory/analgesic agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sulfonylbenzene compounds as anti-inflammatory/analgesic agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3421081